Synopsys (SNPS) Could Be 30% Undervalued After Its Pullback

Synopsys (SNPS) is back in focus after fresh research highlighted expectations for a 41.7% year over year change in current quarter EPS and a history of exceeding recent earnings and revenue estimates.

That upbeat earnings story is landing against a weaker tape, with Synopsys trading at US$381.17 after the share price fell 16.3% over 90 days and 20.7% year to date, while the 5-year total shareholder return of 18.1% points to far more modest longer-term progress.

Compare Synopsys with a curated group of peers by scanning the 29 high quality undervalued stocks, which currently combine earnings power with balance sheet support.

After that kind of reset in Synopsys, the debate is simple. Has the recent pullback cleared the way for fresh upside, or did most of the gain already happen earlier in the cycle?

Most Popular Narrative: 30% Undervalued

On the most followed narrative, Synopsys screens as undervalued, with an implied fair value of about $544.97 compared with the recent $381.17 close. That gap rests heavily on how investors view the next phase of AI driven chip design and the Ansys integration.

The accelerating complexity and proliferation of AI, high-performance computing, and multi-die/chiplet-based architectures are increasing customer demand for Synopsys' advanced design, verification, and simulation solutions, solidifying its role as a mission-critical partner in next-generation chip and system development, supporting both revenue growth and opportunities for higher-margin recurring licensing.

See why 157 investors see Synopsys as 30% undervalued.

Result: Fair Value of $544.97 (UNDERVALUED)

Still, that upbeat Synopsys narrative runs into real friction if export limits keep dragging on China revenue or if the Ansys integration delivers benefits more slowly than expected.

Find out about the key risks to this Synopsys narrative.

Another View on Synopsys Valuation

The first narrative leans on future earnings and a fair value of $544.97 for Synopsys. A simple P/E check tells a different story. The stock trades on about 67.9x earnings, compared with a fair ratio of 44.7x, the US Software industry at 30.3x, and peers around 31.7x. That gap points to meaningful valuation risk if sentiment or earnings expectations slip.

If Synopsys stayed closer to those lower multiples instead of the current 67.9x, the share price would sit on a very different footing. The question is whether you see that premium as justified by the growth narrative, or as a margin of error that could unwind fast.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed signals around Synopsys valuation can be confusing. Use the numbers as a starting point, move quickly, and pressure test the story yourself with the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Synopsys?

Do not stop with Synopsys. Broaden your watchlist now, because the next upgrade to your portfolio probably will not come from a stock you already follow closely.

• Target resilience and sleep better at night by focusing on companies with steadier profiles through the 30 resilient stocks with low risk scores.
• Hunt for quality at a discount and see which businesses combine stronger fundamentals with cheaper tags using the 16 high quality undiscovered gems.
• Prioritize financial strength first and scan a list of solid balance sheet and fundamentals (23 results) before committing fresh capital.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com